The Use of Soluble,Salivary c- erb B-2 for the Detection and Post-operative Follow-up of Breast Cancer in Women: The Results of a Five-year Translational Research Study

Abstract

Get full access to this article

View all access options for this article.

References

Bigler LG, Streckfus CF (2004). A unique protein screening analysis of stimulated whole saliva from normal and breast cancer patients. Preclinica 2(1):52–56.

Bigler LG, Streckfus CF, Copeland L, Burns R, Dai X, Kuhn M, et al. (2002). The potential use of saliva to detect recurrence of disease in women with breast carcinoma. Oral Pathol Med 31:421–431.

Breuer B, Smith S, Thor A, Edgerton S, Osborne MP, Minick R, et al. (1998). ErbB-2 protein in sera and tumors of breast cancer patients. Breast Canc Res Treat 49:261–270.

Brinkley J, Copeland L, Streckfus C, Tucci M, Benguzzi H (2003). Sustained delivery of Her-2/neu antibody by TCPL delivery device using adult male rats as a model. Biomed Sci Inst 39:324–328.

Chen DX, Schwartz PE, Li XG, Yang Z (1988). Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 72:23–27.

Chen DX, Schwartz PE, Li FQ (1990). Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 75:701–704.

Cornelissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC Jr, et al. (1992). Toward a chronotherapy of ovarian cancer part III: salivary CA125 for chronotherapy by efficacy. Chronobiologia 19:131–149.

Hirata Y, Orth DN (1979). Epidermal growth factor (urogastrone) in human fluids: size heterogeneity. J Clin Endocrinol Metab 48:673–679.

Hutchens TW, Yip TT (1993). New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrum 7:576–580.

10.

Jenzano JW, Courts NF, Timko DA, Lundblad RL (1986a). Levels of glandular kallikrein in whole saliva obtained from patients with solid tumors remote from the oral cavity. J Dent Res 65:67–70.

11.

Jenzano JW, Daniel PA, Kent RT, Leal JL, Koth D (1986b). Evaluation of kallikrein in human parotid and submandibular saliva. Arch Oral Biol 31:627–628.

12.

Jenzano JW, Brown CK, Mauriello SM (1987). Temporal variations of glandular kallikrein, protein and amylase in mixed human saliva. Arch Oral Biol 32:757–759.

13.

Jenzano JW, Coffey JC, Heizer WD, Lundblad RL, Scicli AG (1988). The assay of glandular kallikrein and prekallikrein human mixed saliva. Arch Oral Biol 33:641–644.

14.

Kaufman E, Lamster IB (2002). The diagnostic applications of saliva—a review. Crit Rev Oral Biol Med 13:197–212.

15.

Kelsey JL, Horn-Ross PL (1993). Breast cancer: magnitude of the problem and descriptive epidemiology. Epidemiol Rev 15:7–16.

16.

Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL (1995). Efficacy of screening mammography: a meta-analysis. J Am Med Assoc 273:149–154; comment in ACP J Club 123:34–35, 1995; J Am Med Assoc 274:381–382, 1995.

17.

Kosary CL, Ries LAG, Miller BA (1995). Cancer statistics review, 1973–1992. NIH Pub. No. (PHS)95-2789. Bethesda, MD: National Cancer Institute, National Institutes of Health.

18.

Kuerer HM, Thompson PA, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, et al. (2003). High and differential expression of HER2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clin Canc Res 9:601–605.

19.

Lawrence HP (2002). Salivary markers of systemic disease: noninvasive diagnosis of disease and monitoring of general health. J Can Dent Assoc 8:170–174.

20.

Lenhard RE Jr (1996). Cancer statistics: a measure of progress. CA Cancer J Clin 65:5–27; comment 46:5–27.

21.

Li J, Zhang Z, Rosenzweig J, Wang YY, Chan D (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296–1304.

22.

Madoz-Gurpide J, Wang H, Misek DE, Brichory F, Hanash SM (2001). Protein based microarrays: a tool for probing the proteome of cancer cells and tissues. Proteomics 1:1279–1287.

23.

Mandel ID (1993). Salivary diagnosis: promises, promises. Ann NY Acad Sci 694:1–10.

24.

McIntyre R, Bigler L, Dellinger T, Pfeifer M, Mannery T, Streckfus C (1999). Oral contraceptive usage and the expression of CA 15-3 and C-erbB-2 in the saliva of healthy women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88:687–690.

25.

Merchant M, Weinberger SR (2000). Recent advancements in surface enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21:1164–1177.

26.

Michaelson JS, Halpern E, Kopans DB (1999). Breast cancer: computer simulation method for estimating optimal intervals for screening. Radiology 212:551–560.

27.

Morrison AS (1993). Screening for cancer of the breast. Epidemiol Rev 15:244–255.

28.

Nagler RM, Kerner H, Laufer D, Ben-Eliezer S, Minkov I, Ben-Itzhak O (2002). Squamous cell carcinoma of the tongue: the prevalence and prognostic roles of p53, Bcl-2, c-erbB-2 and apoptotic rate as related to clinical and pathological characteristics in a retrospective study. Cancer Lett 186:137–150.

29.

Nagler RM, Kerner H, Ben-Eliezer S, Minkov I, Ben-Itzhak O (2003). Prognostic role of apoptotic, Bcl-2, c-erbB-2, and p53 tumor markers in salivary gland. Oncology 64:389–398.

30.

National Institute of Dental and Craniofacial Research (1999). Workshop on development of new technologies for saliva and other oral fluid-based diagnostics. Airlie House Conference Center, Virginia, September 12–14, 1999, National Institutes of Health.

31.

National Institutes of Health (1997). Consensus development conference statement: breast cancer screening for women ages 40–49, January 21–23, 1997. J Natl Canc Inst 89:1015–1020.

32.

Navarro MA, Mesia R, Diez-Gibert O, Rueda A, Ojeda B, Alonso MC (1997). Epidermal growth factor in plasma and saliva of patients with active breast cancer and breast cancer patients in follow-up compared with healthy women. Breast Cancer Res Treat 42:83–86.

33.

Streckfus CF, Bigler LR (2002). Saliva as a diagnostic fluid. Oral Dis 8:69–76.

34.

Streckfus C, Bigler L, Dellinger T, Pfeifer M, Rose A, Thigpen J (1999). CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Investig 3:138–143.

35.

Streckfus C, Bigler L, Tucci M, Thigpen JT (2000a). A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma. Cancer Invest 18:101–109.

36.

Streckfus C, Bigler L, Dellinger T, Dai X, Kingman A, Thigpen JT (2000b). The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res 6:2363–2370.

37.

Streckfus C, Bigler L, Dellinger T, Dai X, Cox WJ, McArthur A, et al. (2001). Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91:174–179.

38.

Streckfus CF, Bigler L, Dellinger T, Kuhn M, Chouinard N, Dai X (2004). The expression of the c-erbB-2 receptor protein in glandular salivary secretions. J Oral Pathol Med 33:595–600.

39.

Tabak LA (2001). A revolution in biomedical assessment: the development of salivary diagnostics. J Dent Educ 65:1335–1339.

40.

Thesleff I, Viinikka L, Saxén L, Lehtonen E, Perheentupa J (1988). The parotid gland is the main source of human salivary epidermal growth factor. Life Sci 43:13–18.

41.

US Department of Health and Human Services (2000a). Oral health in America: a report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, pp. 279–280.

42.

US Department of Health and Human Services (2000b). Healthy people 2010. 2nd ed. With understanding and improving health and objectives for improving health. 2 vols. Washington, DC: US Government Printing Office, November.

43.

Visco C, Bei R, Moriconi E, Gianni W, Kraus MH, Muraro R (2000). ErbB2 immune response in breast cancer patients with soluble receptor ectodomain. Am J Pathol 156:1417–1424.

44.

Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE (1998). Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma and salivary duct carcinoma. Am J Clin Pathol 109:75–84.

45.

Zabrecky JR, Lam T, Mckenzie SJ, Carney W (1991). The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266:1716–1720.

46.

Zapka JG, Stoddard AM, Costanza ME, Greene HL (1989). Breast cancer screening by mammography: utilization and associated factors. Am J Publ Health 79:1499–1502.